STunning in Acute Myocardial Infarction – Beta blockers, Angiotensin converting enzyme inhibitors and Sodium/glucose cotransporter 2 inhibitors trial (STAMI-BAS)
- Conditions
- Myocardial ischemiaMyocardial infarctionMedDRA version: 20.0Level: LLTClassification code: 10064345Term: ST segment elevation myocardial infarction Class: 10007541Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2024-511789-35-00
- Lead Sponsor
- Vaestra Goetalandsregionen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 120
Patients with STEMI who undergo primary PCI within 6 hours of symptom onset* (*Excluding prodromal symptoms), Informed consent
Killip class = 3, Pre-existing non-reversible cardiac dysfunction or heart failure, Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor, Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician, Life expectancy less than one year, Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception., Additional exclusion criteria for the CMRI sub-study of the trial: 7. Any absolute contraindication for CMRI
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method